-
1.发明授权公开(公告)号：US09271954B2
公开(公告)日：2016-03-01
申请号：US12550780
申请日：2009-08-31
IPC分类号： A61K31/232 , A61K45/06
CPC分类号： A61K31/232 , A61K9/0019 , A61K9/1075 , A61K45/06 , A61K2300/00
摘要： The present invention relates to the use of an oil enriched in docosahexaenoic acid, which is conjugated to triglyceride, for manufacturing a pharmaceutical composition for the treatment of a tumorous disease, said oil being enriched in a concentration of up to 70% by weight in relation to the total weight of said pharmaceutical composition, and said docosahexaenoic acid being in a percentage of at least 50% in relation to the total fatty acids in said oil.
摘要翻译： 本发明涉及与甘油三酯缀合的富含二十二碳六烯酸的油用于制造用于治疗肿瘤疾病的药物组合物的用途，所述油的浓度高达70重量％ 相对于所述药物组合物的总重量，并且所述二十二碳六烯酸的百分比相对于所述油中的总脂肪酸为至少50％。
-
2.发明申请公开(公告)号：US20080207947A1
公开(公告)日：2008-08-28
申请号：US11913994
申请日：2006-04-26
CPC分类号： A61K31/232 , A61K9/0019 , A61K9/1075 , A61K45/06 , A61K2300/00
摘要： The present invention relates to the use of an oil enriched in docosahexaenoic acid, which is conjugated to triglyceride, for manufacturing a pharmaceutical composition for the treatment of a tumorous disease, said oil being enriched in a concentration of up to 70% by weight in relation to the total weight of said pharmaceutical composition, and said docosahexaenoic acid being in a percentage of at least 50% in relation to the total fatty acids in said oil.
摘要翻译： 本发明涉及与甘油三酯缀合的富含二十二碳六烯酸的油用于制造用于治疗肿瘤疾病的药物组合物的用途，所述油的浓度高达70重量％ 相对于所述药物组合物的总重量，并且所述二十二碳六烯酸的百分比相对于所述油中的总脂肪酸为至少50％。
-
3.发明授权Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage 有权使用DHA，EPA或DHA衍生的EPA治疗与细胞氧化损伤相关的病理学公开(公告)号：US09265745B2
公开(公告)日：2016-02-23
申请号：US12158205
申请日：2006-12-20
IPC分类号： A01N37/06 , A61K31/22 , A01N37/02 , A61K31/225 , A01N37/00 , A61K31/20 , A61K31/202 , A23L1/30 , A61K47/12
CPC分类号： A61K8/361 , A23L33/12 , A23V2002/00 , A61K31/202 , A61K47/12 , A61Q19/08
摘要： The present invention relates to the use of an acid enriched in docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or DHA-derived EPA for manufacturing a drug for the treatment of processes that involve associated oxidative damage. In particular, it is for the treatment of processes associated with neurodegenerative, ocular, ischaemic and inflammatory pathology, atherosclerosis, with oxidative damage to DNA and with physical exercise.
摘要翻译： 本发明涉及富含二十二碳六烯酸（DHA）或二十碳五烯酸（EPA）或DHA衍生的EPA的酸的制造用于治疗涉及相关氧化损伤的过程的药物的用途。 特别是用于治疗与神经变性，眼部，缺血和炎性病理学相关的过程，动脉粥样硬化，对DNA的氧化损伤和体育锻炼。
-
4.发明申请USE OF DHA, EPA OR DHA-DERIVED EPA FOR TREATING A PATHOLOGY ASSOCIATED WITH CELLULAR OXIDATIVE DAMAGE 审中-公开使用DHA，EPA或DHA衍生的EPA用于治疗与细胞氧化损伤有关的病理学公开(公告)号：US20130274337A1
公开(公告)日：2013-10-17
申请号：US13803038
申请日：2013-03-14
IPC分类号： A61K31/202 , A23L1/30
CPC分类号： A61K8/361 , A23L33/12 , A23V2002/00 , A61K31/202 , A61K47/12 , A61Q19/08
摘要： The present invention relates to the use of an acid enriched in docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or DHA-derived EPA for manufacturing a drug for the treatment of processes that involve associated oxidative damage. In particular, it is for the treatment of processes associated with neurodegenerative, ocular, ischaemic and inflammatory pathology, atherosclerosis, with oxidative damage to DNA and with physical exercise.
摘要翻译： 本发明涉及富含二十二碳六烯酸（DHA）或二十碳五烯酸（EPA）或DHA衍生的EPA的酸的制造用于治疗涉及相关氧化损伤的过程的药物的用途。 特别是用于治疗与神经变性，眼部，缺血和炎性病理学相关的过程，动脉粥样硬化，对DNA的氧化损伤和体育锻炼。
-
公开(公告)号：US09259408B2
公开(公告)日：2016-02-16
申请号：US13803038
申请日：2013-03-14
IPC分类号： A01N37/06 , A61K31/22 , A01N37/02 , A61K31/225 , A01N37/00 , A61K31/20 , A61K31/202 , A23L1/30 , A61K47/12
CPC分类号： A61K8/361 , A23L33/12 , A23V2002/00 , A61K31/202 , A61K47/12 , A61Q19/08
摘要： The present invention relates to the use of an acid enriched in docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or DHA-derived EPA for manufacturing a drug for the treatment of processes that involve associated oxidative damage. In particular, it is for the treatment of processes associated with neurodegenerative, ocular, ischaemic and inflammatory pathology, atherosclerosis, with oxidative damage to DNA and with physical exercise.
-
6.发明申请公开(公告)号：US20090318553A1
公开(公告)日：2009-12-24
申请号：US12550780
申请日：2009-08-31
IPC分类号： A61K31/232 , A61P35/00
CPC分类号： A61K31/232 , A61K9/0019 , A61K9/1075 , A61K45/06 , A61K2300/00
摘要： The present invention relates to the use of an oil enriched in docosahexaenoic acid, which is conjugated to triglyceride, for manufacturing a pharmaceutical composition for the treatment of a tumorous disease, said oil being enriched in a concentration of up to 70% by weight in relation to the total weight of said pharmaceutical composition, and said docosahexaenoic acid being in a percentage of at least 50% in relation to the total fatty acids in said oil.
摘要翻译： 本发明涉及与甘油三酯缀合的富含二十二碳六烯酸的油用于制造用于治疗肿瘤疾病的药物组合物的用途，所述油的浓度高达70重量％ 相对于所述药物组合物的总重量，并且所述二十二碳六烯酸的百分比相对于所述油中的总脂肪酸为至少50％。
-
7.发明申请Use of Dha, Epa or Dha-Derived Epa for Treating a Pathology Associated with Cellular Oxidative Damage 有权使用Dha，Epa或Dha衍生的Epa来治疗与细胞氧化损伤相关的病理学公开(公告)号：US20080292681A1
公开(公告)日：2008-11-27
申请号：US12158205
申请日：2006-12-20
IPC分类号： A61K31/202 , A23L1/30 , A61P25/00 , A61P9/00 , A61P21/00
CPC分类号： A61K8/361 , A23L33/12 , A23V2002/00 , A61K31/202 , A61K47/12 , A61Q19/08
摘要： The present invention relates to the use of an acid enriched in docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or DHA-derived EPA for manufacturing a drug for the treatment of processes that involve associated oxidative damage. In particular, it is for the treatment of processes associated with neurodegenerative, ocular, ischaemic and inflammatory pathology, atherosclerosis, with oxidative damage to DNA and with physical exercise.
摘要翻译： 本发明涉及富含二十二碳六烯酸（DHA）或二十碳五烯酸（EPA）或DHA衍生的EPA的酸的制造用于治疗涉及相关氧化损伤的过程的药物的用途。 特别是用于治疗与神经变性，眼部，缺血和炎性病理学相关的过程，动脉粥样硬化，对DNA的氧化损伤和体育锻炼。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.013 秒)
